WEST Search History

DATE: Wednesday, January 29, 2003

Set Name side by side	Query	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
DB=USPT; $PLUR=YES$; $OP=ADJ$			
L13	L12 and @ay<2001	97	L13
L12	(quinazolinone benzoxazole benzimidazole benzothiazole indole) with prodrug	104	L12
L11	(quinazolinone benzoxazole benzimidazole benzothiazole indole) same prodrug	126	L11
DB = J	IPAB,EPAB,DWPI; PLUR=YES; OP=ADJ		
L10	boron insolubilization therapy or boron capture therapy	()	L10
DB=PGPB; $PLUR=YES$; $OP=ADJ$			
L9	L8	0	L9
DB=USPT; $PLUR=YES$; $OP=ADJ$			
L8	boron insolubilization therapy or boron capture therapy	2	L8
L7	L6 and @ay<2001	52	L7
L6	prodrug with (precipitat\$ insolubl\$)	59	L6
L5	L3 and @ay<2001	95	L5
L4	L3 and (@)ad<2001	0	L4
L3	L2 same prodrug	98	L3
L2	enzyme near3 target\$	3429	L2
L1	5762918.pn.	1	L1

END OF SEARCH HISTORY

FILE 'HOME' ENTERED AT 11:04:17 ON 29 JAN 2003

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 11:04:28 ON 29 JAN 2003

64 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

- => s boron insolubilization therapy
 - 12 FILES SEARCHED...
 - 29 FILES SEARCHED...
 - 49 FILES SEARCHED...
 - O FILES HAVE ONE OR MORE ANSWERS, 64 FILES SEARCHED IN STNINDEX
- L1 QUE BORON INSOLUBILIZATION THERAPY
- => s boron insolubil? therapy
 - 24 FILES SEARCHED...
 - 49 FILES SEARCHED...
 - O FILES HAVE ONE OR MORE ANSWERS, 64 FILES SEARCHED IN STNINDEX
- L2 QUE BORON INSOLUBIL? THERAPY
- => s insolubil?(10a)therapy
 - 3 FILE BIOSIS
 - 4 FILE CAPLUS
 - 1 FILE CONFSCI
 - 24 FILES SEARCHED...
 - 1 FILE EMBASE
 - 1 FILE ESBIOBASE
 - 1 FILE MEDLINE
 - 1 FILE NTIS
 - 2 FILE SCISEARCH
 - 58 FILES SEARCHED...
 - 2 FILE USPATFULL
 - 1 FILE USPAT2
 - 1 FILE WPIDS
 - 1 FILE WPINDEX
 - 12 FILES HAVE ONE OR MORE ANSWERS, 64 FILES SEARCHED IN STNINDEX
- L3 QUE INSOLUBIL? (10A) THERAPY
- => d rank
- F1 4 CAPLUS
- F2 3 BIOSIS
- F3 2 SCISEARCH
- F4 2 USPATFULL

F5 CONFSCI 1 F6 1 EMBASE F7 1 ESBIOBASE F8 MEDLINE 1 F9 1 NTIS F10 1 USPAT2 F11 1 WPIDS F12 1 WPINDEX => file hits COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 3.30 3.51 FILE 'CAPLUS' ENTERED AT 11:07:46 ON 29 JAN 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS) FILE 'BIOSIS' ENTERED AT 11:07:46 ON 29 JAN 2003 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R) FILE 'SCISEARCH' ENTERED AT 11:07:46 ON 29 JAN 2003 COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R) FILE 'USPATFULL' ENTERED AT 11:07:46 ON 29 JAN 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS) FILE 'CONFSCI' ENTERED AT 11:07:46 ON 29 JAN 2003 COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA) FILE 'EMBASE' ENTERED AT 11:07:46 ON 29 JAN 2003 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved. FILE 'ESBIOBASE' ENTERED AT 11:07:46 ON 29 JAN 2003 COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved. FILE 'MEDLINE' ENTERED AT 11:07:46 ON 29 JAN 2003 FILE 'NTIS' ENTERED AT 11:07:46 ON 29 JAN 2003 Compiled and distributed by the NTIS, U.S. Department of Commerce. It contains copyrighted material. All rights reserved. (2003) FILE 'USPAT2' ENTERED AT 11:07:46 ON 29 JAN 2003 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS) FILE 'WPIDS' ENTERED AT 11:07:46 ON 29 JAN 2003 COPYRIGHT (C) 2003 THOMSON DERWENT FILE 'WPINDEX' ACCESS NOT AUTHORIZED => s 13 and py<2001 2 FILES SEARCHED... '2001' NOT A VALID FIELD CODE 6 FILES SEARCHED... 9 FILES SEARCHED... 7 L3 AND PY<2001 => dup rem 14

PROCESSING COMPLETED FOR L4
L5 7 DUP REM L4 (0 DUPLICATES REMOVED)
ANSWERS '1-3' FROM FILE CAPLUS
ANSWER '4' FROM FILE BIOSIS

ANSWER '5' FROM FILE USPATFULL ANSWER '6' FROM FILE EMBASE ANSWER '7' FROM FILE WPIDS => d bib abs 1-7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS 1975:403897 CAPLUS AN 83:3897 Study of the translocation of radiostrontium from wounds and therapy by local insolubilization Ducousso, Roger; Causse, Andre; Pasquier, Christian CS Groupe Rech. Serv. Sante Armees, Comm. Energ. At., Fontenay-aux-Roses, Fr. Proc. Int. Congr. Int. Radiat. Prot. Assoc., 3rd (1974), Meeting SO Date 9 Sep 1973-14 Sep 1973, Volume 2, Issue CONF-730907-P2, 1418-21. Editor(s): Snyder, Walter S. Publisher: NTIS, Springfield, Va. CODEN: 301KAD Conference LA English The translocation of 85Sr was followed by a 2-hr external counting of the AB wound and homol. bone and by measurement of the blood radioactivity. types of wounds were simulated on monkeys; viz., puncture wounds and lacerations. The same exptl. procedure was applied in order to test therapy through Sr insoslubilization by K rhodizonate, Mg SO4, Ca alginate and Al PO4 gel, on laceration wounds either 5 or 15 min after the contamination. Local or iv. administration of DTPA did not increase absorption of Sr. L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS AN 1974:532298 CAPLUS DN 81:132298 Study of the translocation of radiostrontium from wounds and therapy by local insolubilization ΑU Ducousso, R.; Causse, A.; Pasquier, C. CS CEN, Commis. Energ. At., Fontenay-aux-Roses, Fr. Report (1973), CEA-CONF-2542, 4 pp. Avail.: Dep. NTIS (U. S. Sales Ony), CEA From: Nucl. Sci. Abstr. 1974, 29(12), 29865 DТ Report LA English The translocation of 85Sr was followed by external counting of the wound and homologous bone during a 2-hr period and by measurement of the blood radioactivity following uptake from 2 types of wounds simulated on Maccacus monkeys, viz., puncture wounds and lacerations. The same procedure was applied in order to test therapy using Krhodizonate, MgSO4, Cu alginate, or Al phosphate gel for theremoval of Sr from laceration wounds either 5 or 15 min after contamination. Local or i.v. administration of DTPA did not increase absorption of Sr. ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS 1927:3186 CAPLUS DN 21:3186 OREF 21:378c-q Some derivatives of anesthesine Gori, G. Gazz. chim. ital. (1926), 56, 430-4 Journal Unavailable For diagram(s), see printed CA Issue. The use of anesthesine, P-H2NC6H4CO2Et (I) in therapy is very limited on account of its insoly. in H2O, and moreover previous

attempts by various workers to prep. H2O-sol. derivs. of the same or superior therapeutic value have been unsuccessful. Undertaking this problem, G. prepd. numerous new derivs. and tested their physiol. action. I and (CH2CO2H)2 (equimol. wts.) heated at 180.degree., cooled and extd.

 L_5

DN

ΤT

AU

DT

TT

SO

AB

1.5

ΑN

ΤI

ΑU

SO

DT

LA

GT

AB

with boiling EtOH, gave the (CH2CO2H)2 deriv., EtO2CC6H4N.CO.CH2.CH2.CO, m. 150.degree., odorless, tasteless, has no anesthetic (analgesic) power (in contrast to the analogous succinyl-p-phenetidine, which retains the antipyretic power of p-phenetidine). In a similar way I and C6H4(CO2)O at 150-60.degree. gave 90% of the C6H4(CO2)O deriv., EtO2CC6H4N. CO. C6H4.CO, m. 150-1.degree., odorless, tasteless, has no anesthetic properties. I and 1,2-Cl4C6(CO2H)2 gave the Cl4C6(CO2H)2 deriv., EtO2CC6H4N.CO.C6Cl4.CO, yellow-white, m. 255.degree., unctuous, odorless, tasteless, has no anesthetic properties. I and piperonal at 95-8.degree. gave the piperonal deriv., EtO2CC6H4N:CHC6H4.O.CH2O, bright yellow, m. 109-10.degree., faint heliotrope odor, tasteless, has no anesthetic properties. I (3.3 g.), 1,2,4-ClC6H3(NO2)2 (4.1 g.), AcONa (2 g.) and EtOH (50 cc.) boiled 5 hrs. gave the ClC6H3(NO2)2, deriv., p-EtO2CC6H4NHC6H4(NO2)2, orange, m. 112-3.degree. odorless, tasteless, has no anesthetic properties. I (3.3 g.), CS2 (1 g.), EtOH (30 cc.) and H2O2, (2-4 cc.) agitated, let stand 12 hrs., the ppt. sepd., and the process repeated 5-6 times with addn. of a little H2O2 each time, and the ppts. purified in EtOH, gave the CS2 deriv., (P-EtO2CC6H4NH)2CS, bright yellow, m. 153.degree., odorless, tasteless, has no anesthetic properties. The physiol. tests on all the compds. confirmed the work of Thoms and Ritsert (C. A. 15, 2851) that substitution of H atoms in the NH2 group reduces the physiol, action.

ANSWER 4 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. L5 AN 1972:78173 BIOSIS DN BR08:78173 TICANCER IMMUNO THERAPY USING AUTOLOGOUS TUMOR TISSUE INSOLUBILIZED WITH ETHYL CHLOR FORMIATE. TALLBERG T; LEMPINEN M; HJELT L; TURUNEN M; PAILE W; JOKINEN E J; ALFTHAN ΑU Acta Pathol. Microbiol. Scand., Sect. B: Microbiol. Immunol., (1972) 80 SO (1), 174. CODEN: APMIBM. ISSN: 0365-5563. DΤ Conference FS BR; OLD LA Unavailable ANSWER 5 OF 7 USPATFULL L580:63114 USPATFULL ANTIWater-soluble salts of tienilic acid Laforest nee Boutillier du Retail, Jacqueline S., Vincennes, France INBessin, Pierre A. R., Chilly-Mazarin, France PΑ Albert Rolland S.A., Paris, France (non-U.S. corporation) <---PΙ US 4239771 19801216 US 1978-929114 19780728 (5) ΑI PRAI FR 1977-24061 19770804 DTUtility FS Granted Primary Examiner: Trousof, Natalie; Assistant Examiner: Hendriksen, L. EXNAM Stevens, Davis, Miller & Mosher LREP Number of Claims: 7 CLMN ECL Exemplary Claim: 1,7 DRWN No Drawings LN.CNT 133 CAS INDEXING IS AVAILABLE FOR THIS PATENT. The invention provides water-soluble salts of tienilic acid,

2,3-dichloro-4-(2-thienylcarbonyl)-phenoxyacetic acid, and amino acids of the formula ##STR1## in which n is an integer of 1 to 5 and R represents a basic nitrogenous group, preferably an amino group or guanidino group. These salts, unlike the parent acid are water-soluble

guanidino group. These salts, unlike the parent acid are water-solubl and are of good biodisponibility and may be used in injectable form, e.g. for emergency treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 7 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

86008327 EMBASE AN DN 1986008327 ΤI Antiviral therapy in the immunocompromised patient. Prentice H.G.; Hann I.M. ΑU Department of Haematology, Royal Free Hospital and Medical School, London, CS United Kingdom SO British Medical Bulletin, (1985) 41/4 (367-373). CODEN: BMBUAQ CY United Kingdom DT Journal FS 037 Drug Literature Index 047 Virology 026 Immunology, Serology and Transplantation 030 Pharmacology 025 Hematology 006 Internal Medicine 016 Cancer LA English The viral infections encountered in the compromised host are remarkable AΒ for the relatively small number of causative organisms. Although children with acute leukaemia may suffer fatal measles infections and other viral illness common to the normal host, the latent DNA viruses pose by far the greatest numerical problem. These are represented by the herpes family and hepatitis B. The major advances in antiviral therapy and prophylaxis of recent years have been limited to the treatment and subsequently prophylaxis of the herpes group infections. Acyclovir has been shown to be effective in the treatment of established herpes simplex (HSV) and varicella zoster infection (VZV), but not cytomegalovirus (CMV) or Epstein-Barr virus (EBV). Adenine arabinoside is also of proven activity in the same infections but is less easy to administer due to its insolubility and myelotoxicity. Topical antiviral therapy is not usually indicated in these patients because of the high risk of dissemination. The true value of newer antiviral agents will become easier to evaluate as the rapid diagnosis of viral infection is improved by the use or monoclonal antibodies, gene probes and other products of molecular biology. This is especially the case in CMV infection, which remains a major problem for which new effective agents are urgently needed in conditions such as CMV pneumonia, a major cause of mortality after marrow and organ transplants. The introduction of immunoprophylaxis has shown some promise and the therapeutic use of high-titre CMV immunoglobulin appears to be effective in some cases. Similarly, the use of zoster immunoglobulin is established in susceptible VZV contacts. The use of high-titre measles immunoglobulin requires further study. ANSWER 7 OF 7 WPIDS (C) 2003 THOMSON DERWENT L_5 AN 1972-11578T [08] WPIDS ΤI Tetracycline condensation products - with sulphonamides and formaldehyde or glyoxal. DC PA (ANKE-N) ANKERMANN & CO; (ANKE) ANKERMANN AND CO VITAMINC CYC CH 516518 Α (197208)*A 19720413 (198542) DE 1768510 PRAI DE 1968-1768510 19680520 AN1972-11578T [08] WPIDS

CH 516518 A UPAB: 19930000 Condensation products prepared by reacting a tetracycline with formaldeyde or glyoxal and a sulphonamide (e.g. sulphaguanidine or sulphathiazole) are practically insoluble in water and dilute acids. Because of their insolubility they are tasteless and are thus advantageous in oral tetracycline therapy, particularly with children.

=> file stnguide
COST IN U.S. DOLLARS

AB

FULL ESTIMATED COST ENTRY SESSION 55.90 59.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY
SESSION
CA SUBSCRIBER PRICE

-1.95
-1.95

FILE 'STNGUIDE' ENTERED AT 11:13:07 ON 29 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 24, 2003 (20030124/UP).

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 11:15:01 ON 29 JAN 2003

SINCE FILE

SINCE FILE

ENTRY 0.18

ENTRY 0.00 TOTAL SESSION

59.59

TOTAL

-1.95

SESSION

64 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s boron capture therapy

CA SUBSCRIBER PRICE

- 1 FILE BIOBUSINESS
- 5 FILE BIOSIS
- 1 FILE BIOTECHNO
- 1 FILE CABA
- 3 FILE CANCERLIT
- 37 FILE CAPLUS
- 1 FILE CONFSCI
- 1 FILE DDFU

24 FILES SEARCHED...

- 1 FILE DRUGNL
- 1 FILE DRUGU
- 1 FILE DRUGUPDATES
- 4 FILE EMBASE
- 2 FILE FEDRIP
- 1 FILE LIFESCI
- 4 FILE MEDLINE

47 FILES SEARCHED...

- 1 FILE NTIS
- 5 FILE SCISEARCH
- 5 FILE TOXCENTER
- 0* FILE WPINDEX
- 18 FILES HAVE ONE OR MORE ANSWERS, 64 FILES SEARCHED IN STNINDEX
- L6 QUE BORON CAPTURE THERAPY
- => s 16 and (insolubil? or precipitat?) and py<2001
 - 0* FILE ADISINSIGHT
 - 5 FILES SEARCHED...

```
9 FILES SEARCHED...
```

- 13 FILES SEARCHED...
- 16 FILES SEARCHED...
 - 0* FILE CONFSCI
- 20 FILES SEARCHED...
- 25 FILES SEARCHED...
- 33 FILES SEARCHED...
 - 0* FILE FEDRIP
 - 0* FILE FOREGE
- 41 FILES SEARCHED...
 - 0* FILE MEDICONF
- 46 FILES SEARCHED...
- 50 FILES SEARCHED...
 - 0* FILE PHAR
- 56 FILES SEARCHED...
- 63 FILES SEARCHED...
 - 0* FILE WPINDEX
- O FILES HAVE ONE OR MORE ANSWERS, 64 FILES SEARCHED IN STNINDEX
- L7 QUE L6 AND (INSOLUBIL? OR PRECIPITAT?) AND PY<2001

=> log y

SINCE FILE TOTAL ENTRY SESSION COST IN U.S. DOLLARS FULL ESTIMATED COST 20.90 80.49 SINCE FILE TOTAL DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) ENTRY SESSION CA SUBSCRIBER PRICE 0.00 -1.95

STN INTERNATIONAL LOGOFF AT 11:38:04 ON 29 JAN 2003